John Cullivan Joins PCI Pharma Services as Chief Corporate Development Officer

PCI Focuses on Global Growth to Meet Evolving Client Needs

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced that John Cullivan has joined the Company as a new member of the Executive Leadership Team in the role of Chief Corporate Development Officer. John will play a key role in PCI’s growth strategy and will accelerate its M&A, focusing on acquisitions to enhance PCI’s capabilities, enter new markets and geographies, and strengthen its portfolio of client solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005160/en/

John Cullivan joins PCI Pharma Services as Chief Corporate Development Officer (Photo: Business Wire)

“I look forward to working with John to expand PCI’s global footprint and our offerings to clients, who are bringing life-changing therapies to patients around the world,” said Salim Haffar, CEO, PCI Pharma Services. “John is an M&A expert with significant CDMO experience and a strong track record of success. He brings great value to PCI and our clients, and I am excited to welcome him to the Company.”

Mr. Cullivan joins PCI with over 20 years of experience in corporate development leadership roles at large global life sciences organizations. Prior to joining PCI, he led Corporate Development at Albany Molecular Research Inc. (AMRI). Before that, he held several leadership positions, including Senior Vice President (SVP) of Corporate Development and Strategy for Lonza; head of Corporate Development and Strategy for Capsugel, where he helped transform the company to a Specialty CDMO; and SVP of Corporate Development and Strategy for Cardinal Health.

“I am thrilled to join PCI and build upon the growth and innovation that has brought so much benefit to our clients and the company already,” says Mr. Cullivan. “I look forward to partnering with our talented colleagues to execute an acquisition strategy that strengthens our position as a leading integrated, global supply chain solutions provider founded on a culture of excellence and exceptional client service.”

Mr. Cullivan holds an MBA from the Massachusetts Institute of Technology (MIT) Sloan School of Management and a B.S. in Aerospace Engineering from the United States Military Academy at West Point. He is a former captain and air cavalry helicopter pilot in the U.S. Army and a veteran of the Persian Gulf War.

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005160/en/